ABBV
AbbVie Inc.
NYSE · Healthcare · Drug Manufacturers - General · US
$292.01
+2.10%Nov 4, 2026, 06:30 UTC
Nxera Pharma UK Ltd. entered an exclusive global license agreement with AbbVie for Nxera's EP4 agonist program, including NXE0033744, for an upfront payment of US$100 million.
Nov 4, 2026, 00:08 UTC
AbbVie Inc. expanded its Oxford research and development facility as part of an investment exceeding £120 million.
Source:Nov 3, 2026, 13:00 UTC
AbbVie Inc. announced that it will present nine abstracts at the 2026 ASDS Annual Meeting in San Diego on November 5–8, 2026.
Source:Nov 2, 2026, 21:31 UTC
AbbVie reported that Class II director Jennifer L. Davis departed from the board, effective November 2, 2026.
Oct 30, 2026, 17:11 UTC
AbbVie Inc. shares rose after the company raised its 2026 earnings-per-share outlook.
Source:Oct 30, 2026, 11:49 UTC
AbbVie Inc. announced a 5.2% increase in its dividend, effective with dividends paid from February 2027.
Source:Oct 30, 2026, 11:46 UTC
AbbVie Inc. reported third-quarter 2026 net revenues of $17.404 billion, up 10.3% year over year, and diluted EPS of $2.37 on a GAAP basis and $3.82 on an adjusted basis.
Oct 28, 2026, 12:00 UTC
BOTOX® Cosmetic Day is scheduled to return on November 18, 2026, with an offer for AbbVie Inc. members.
Source:Oct 27, 2026, 12:30 UTC
AbbVie Inc. announced that BOTOX Cosmetic awarded 20 women entrepreneurs grants of $20,000 each through AbbVie Inc. in 2026.
Source:Oct 27, 2026, 12:00 UTC
AbbVie Inc. submitted a Biologics License Application to the U.S. Food and Drug Administration for etentamig to treat adults with relapsed or refractory multiple myeloma.
Source:Oct 26, 2026, 00:08 UTC
AbbVie Inc. announced that its epcoritamab injection, marketed as EPKINLY, launched in China for relapsed or refractory follicular lymphoma.
Oct 23, 2026, 19:33 UTC
The U.S. Food and Drug Administration approved an update to SKYRIZI’s U.S. prescribing information to allow healthcare providers to use clinical judgment in determining whether tuberculosis testing is needed.
Source:Oct 23, 2026, 19:33 UTC
The U.S. Food and Drug Administration approved a subcutaneous induction regimen of AbbVie Inc.’s SKYRIZI for adults with moderately to severely active Crohn’s disease.
Source:Oct 22, 2026, 13:00 UTC
AbbVie Inc. announced positive topline Phase 3 INTREPID results, reporting that lutikizumab met the primary HiSCR75 endpoint at Week 16 versus placebo and eight ranked secondary endpoints in patients with moderate to severe hidradenitis suppurativa.
Source:Oct 22, 2026, 07:15 UTC
Brazil’s health regulator Brazilian Health Regulatory Agency approved AbbVie Inc.’s Emrelis for certain adults with advanced or metastatic non-squamous non-small cell lung cancer with high c-Met levels.
Source:Oct 21, 2026, 22:46 UTC
AbbVie Inc. shares closed at $284.80, down 1.48% from the previous close.
Source:Oct 21, 2026, 12:00 UTC
AbbVie Inc. announced that it will present eight scientific posters and host educational activities at AMWC Dubai from October 21 to 23, 2026.
Source:Oct 21, 2026, 11:05 UTC
AbbVie Inc. reached an agreement with the pan-Canadian Pharmaceutical Alliance concerning ELAHERE.
Source:Oct 20, 2026, 11:55 UTC
AbbVie Inc. and MCLAREN RACING LIMITED announced a multi-year partnership naming AbbVie Inc. the Official Pharmaceutical Partner of the MCLAREN RACING LIMITED and launching the AbbVie Inc. Race to Innovate campaign.
Source:Oct 20, 2026, 10:32 UTC
Zelgen announced that it received a $10 million milestone payment from AbbVie Inc. under their global strategic collaboration and license option agreement for ZG006, based on clinical-trial progress.
Source:Oct 19, 2026, 08:00 UTC
AbbVie Inc. reported that ABBV-466 achieved higher endoscopic remission rates at Week 12 than anti-IL-23 p19 or anti-α4β7 monotherapy in a Phase 2a Crohn’s disease study, with the treatment difference increasing at Week 24.
Source:Oct 15, 2026, 20:06 UTC
AbbVie appointed John M. Carethers as a Class II director, effective October 14, 2026.
Oct 12, 2026, 22:45 UTC
AbbVie Inc. shares closed at $281.04, up 1.65% from the previous close.
Source:Oct 5, 2026, 22:46 UTC
AbbVie (ABBV) closed at $265.85, up 1.15% from the prior trading session.
Source:Oct 5, 2026, 20:12 UTC
AbbVie Inc. updated its Q3 2026 and FY2026 earnings guidance, citing $216 million in acquired IPR&D and milestones expense for Q3 and $1,251 million for the full year.
Oct 5, 2026, 18:49 UTC
Genmab and AbbVie announced positive topline results from the Phase 3 EPCORE DLBCL-2 trial showing epcoritamab in combination with R-CHOP achieved statistically significant improvement in progression-free survival in newly diagnosed diffuse large B-cell lymphoma patients, and will engage global regulatory authorities.
Oct 1, 2026, 14:00 UTC
AbbVie presented late-breaking Phase 3 Viti-Up-1 and Viti-Up-2 data at the 2026 EADV Congress in Vienna showing continued facial and total body repigmentation with RINVOQ (upadacitinib) in non-segmental vitiligo through week 76.
Source:Sep 30, 2026, 05:30 UTC
AbbVie announced positive primary results from the Phase 2 APEX Part B study of zumilokibart in adults with moderate to severe atopic dermatitis, with all three dose regimens meeting the primary endpoint and the mid-dose selected for Phase 3 development.
Source:
Page 1Next →